CoChat
Sign Up
Cited by 234Substance Abuse Treatment and OutcomesOpioid Use Disorder TreatmentNeurotransmitter Receptor Influence on Behavior

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Bupropion for the Treatment of Methamphetamine Dependence

Elkashef, Ahmed M, Rawson, Richard A, Anderson, Ann L, Li, Shou-Hua, Holmes, Tyson, Smith, Edwina V, Chiang, Nora, Kahn, Roberta, Vocci, Frank, Ling, Walter, Pearce, Valerie J, McCann, Michael, Campbell, Jan, Gorodetzky, Charles, Haning, William, Carlton, Barry, Mawhinney, Joseph, Weis, Dennis·2008·Neuropsychopharmacology
DOI 10.1038/sj.npp.1301481
Open this paper in CoChat — free account

Abstract

Bupropion was tested for efficacy in increasing weeks of abstinence in methamphetamine-dependent patients, compared to placebo. This was a double-blind placebo-controlled study, with 12 weeks of treatment and a 30-day follow-up. Five outpatient substance abuse treatment clinics located west of the Mississippi participated in the study. One hundred and fifty-one treatment-seekers with DSM-IV diagnosis of methamphetamine dependence were consented and enrolled. Seventy-two participants were randomized to placebo and 79 to sustained-release bupropion 150 mg twice daily. Patients were asked to come to the clinic three times per week for assessments, urine drug screens, and 90-min group psychotherapy. The primary outcome was the change in proportion of participants having a methamphetamine-free week. Secondary outcomes included: urine for quantitative methamphetamine, self-report of methamphetamine use, subgroup analyses of balancing factors and comorbid conditions, addiction severity, craving, risk behaviors for HIV, and use of other substances. The generalized estimating equation regression analysis showed that, overall, the difference between bupropion and placebo groups in the probability of a non-use week over the 12-week treatment period was not statistically significant (p=0.09). Mixed model regression was used to allow adjustment for baseline factors in addition to those measured (site, gender, level of baseline use, and level of symptoms of depression). This subgroup analysis showed that bupropion had a significant effect compared to placebo, among male patients who had a lower level of methamphetamine use at baseline (p<0.0001). Comorbid depression and attention-deficit/hyperactivity disorder did not change the outcome. These data suggest that bupropion, in combination with behavioral group therapy, was effective for increasing the number of weeks of abstinence in participants with low-to-moderate methamphetamine dependence, mainly male patients, regardless of their comorbid condition.

Overview

Integrity signals

Registry

Crossref · 10.1038/sj.npp.1301481

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 42 references

Research works printed but not linked: 1

  1. Somoza E, Baker S, Himmler C, LoCastro J, Mezinskis J, Simon S et al (2000). The brief substance craving scale—measuring craving in a clinical trial. Presented at the 61st Annual Scientific Meeting of the College on Problems of Drug Dependence, 1999. NIDA Res Monogr 180: 304.

Cited by

Sorted by citations

Items 101–200 of 234

Related

See all

Metadata

Authors
Elkashef, A. M., Rawson, R. A., Anderson, A. L., Li, S.-H., Holmes, T., Smith, E. V., Chiang, N., Kahn, R., Vocci, F., Ling, W., Pearce, V. J., McCann, M., Campbell, J., Gorodetzky, C., Haning, W., Carlton, B., Mawhinney, J., & Weis, D.
Affiliations
  • National Institutes of Health (US)
  • University of California, Los Angeles (US)
  • Stanford Medicine (US)
  • Matrix Institute on Addictions (US)
  • University of Missouri–Kansas City (US)
  • IQVIA (United Kingdom) (GB)
  • University of Hawaiʻi at Mānoa (US)
Corresponding author
Elkashef, Ahmed M
ORCID
Venue
Neuropsychopharmacology
Publisher
Springer Science and Business Media LLC
Published
2007-06-20
Volume
33
Issue
5
Pages
1162-1170
ISSN
  • 0893-133X (ISSN-L)
  • 1740-634X
DOI
10.1038/sj.npp.1301481
OpenAlex
W2003590685
Cited by
234
References
42
Citations by year
2026: 12 · 2025: 7 · 2024: 8 · 2023: 13 · 2022: 9 · 2021: 9 · 2020: 6 · 2019: 5 · 2018: 10 · 2017: 8 · 2016: 15 · 2015: 16 · 2014: 22 · 2013: 19 · 2012: 14
FWCI
10.78
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Neuropsychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institute on Drug Abuse (N01DA-3-8824, N01-DA-0-8804)
Topics
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
bupropion, methamphetamine dependence, cocaine dependence, abstinence, bupropion sustained release, group therapy, comorbid depression, attention deficit hyperactivity disorder, craving, HIV risk behavior, substance use disorders
MeSH terms
Adult, Double-Blind Method, Female, Follow-Up Studies, Humans, Male, Methamphetamine, Middle Aged, Mississippi, Psychotherapy, Severity of Illness Index, Bupropion, Treatment Outcome, Dopamine Uptake Inhibitors, Amphetamine-Related Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review